NeoStem to Present at Multiple June Conferences

NeoStem Inc. Logo

NEW YORK, May 28, 2014 (GLOBE NEWSWIRE) -- NeoStem, Inc. (Nasdaq:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy industry, announced today that the Company will present at multiple upcoming conferences in June. In addition, Phase 1 data licensed from the University of California, San Francisco (UCSF) by NeoStem for its T regulatory cell product candidate for type 1 diabetes, is expected to be presented by Dr. Stephen Gitelman of UCSF, on June 15 at the American Diabetes Association's 74th Scientific Sessions in San Francisco.

American Society of Clinical Oncology 50th Annual Meeting

  • Date and Time: Sunday, June 1, 2014, 8:00 AM – 11:45 AM CDT
  • Venue: McCormick Place, Chicago, Illinois
  • Website:
  • Poster Presenter: Dr. Robert Dillman, Vice President of Oncology, NeoStem Oncology
  • Topic: Long-term survival for patients with detectable metastatic melanoma at time of treatment with patient-specific tumor stem cell vaccines

Jefferies Global Healthcare Conference

  • Date and Time: Monday, June 2, 2014, 11:30 AM EDT
  • Venue: Grand Hyatt, New York, New York
  • Website:
  • Presenter: Dr. Robin Smith, Chairman and CEO, NeoStem
  • Topic: NeoStem Company Presentation

Lugano Stem Cell Meeting

Session 1:

  • Date and Time: Tuesday, June 23, 2014, 11:10 AM CET
  • Panelist: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Industry Session

Session 2:

  • Date and Time: Tuesday, June 23, 2014, 11:50 AM CET
  • Speaker: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: CD34 Cell Therapy for Ischemic Tissue Repair

Session 3:

  • Date and Time: Tuesday, June 23, 2:05 PM CET
  • Panelist: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Stem Cell Manufacturing and Characterization

Session 4:

  • Date and Time: Wednesday, June 24, 2014, 10:55 AM CET
  • Panel Chairman: Dr. Douglas Losordo, Chief Medical Officer, NeoStem
  • Topic: Clinical Trials: Long Term Results and Their Impact for Future Trials

2014 BIO International Convention

  • Date and Time: Tuesday, June 24, 2014, 3:00 PM PDT
  • Venue: San Diego Convention Center, San Diego, California
  • Website:
  • Presenter: Dr. Robert Preti, Chief Scientific Officer, NeoStem and PCT; President, PCT
  • Topic: Targeting the End Game: Keys to Reaching Commercial Viability by Establishing the Right GMP Processes for Cell Therapy Clinical Trials from Processing to Delivery to the Patient

About NeoStem, Inc.

NeoStem is a leader in the emerging cellular therapy industry, pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. The business includes the development of novel proprietary cell therapy products as well as a revenue-generating contract development and manufacturing service business. This combination has created an organization with unique capabilities for cost effective in-house product development and immediate revenue and cash flow generation.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy, the Company's ability to develop and grow its business, the successful development of cellular therapies with respect to the Company's research and development and clinical evaluation efforts in connection with the Company's Targeted Immunotherapy Program, CD34 Cell Program, T Regulatory Cell Program and other cell therapies, the future of the regenerative medicine industry and the role of stem cells and cellular therapy in that industry and the performance and planned expansion of the Company's contract development and manufacturing business. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the "Risk Factors" described in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission ("SEC") on March 13, 2014, the Company's Current Report on Form 8-K filed with the SEC on May 8, 2014 and in the Company's other periodic filings with the SEC. The Company's further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Investor Contact: LifeSci Advisors, LLC Michael Rice Founding Partner Phone: +1-646-597-6979 Email: Media Contact: NeoStem, Inc. Eric Powers Manager of Communications and Marketing Phone: +1-212-584-4173 Email:

Source:NeoStem Inc.